March 8, 2002 Page 1 of 4
Fact Sheet: Anthrax Information for Health Care Providers
Cause Bacillus anthracis Encapsulated, aerobic, gram-positive, spore-forming, rod-shaped (bacillus) bacterium
Systems Affected
Skin or cutaneous (most common) Respiratory tract or inhalation (rare) Gastrointestinal (GI) tract (rare) Oropharyngeal form (least common)
Transmission Skin: direct skin contact with spores; in nature, contact with infected animals or animal products (usually related to occupational exposure) Respiratory tract: inhalation of aerosolized spores GI: consumption of undercooked or raw meat products or dairy products from infected animals NO person-to-person transmission of inhalation or GI anthrax
Reporting Report suspected or confirmed anthrax cases immediately to your local or state department of health.
Cutaneous Anthrax Incubation Period Usually an immediate response up to 1 day Typical Signs/Symptoms
Local skin involvement after direct contact with spores or bacilli Localized itching followed by 1) papular lesion that turns vesicular and 2) subsequent development of black eschar within 7–10 days of initial lesion
Treatment (See “Cutaneous Anthrax Treatment Protocol” for specific therapy*)
Obtain specimens for culture BEFORE initiating antimicrobial therapy.Do NOT use extended-spectrum cephalosporins or trimethoprim/sulfamethoxazole because anthrax may be resistant to these drugs.
Precautions Standard contact precautions. Avoid direct contact with wound or wound drainage.
* http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm
Fact Sheet: Anthrax Information for Health Care Providers (continued from previous page)
March 8, 2002 Page 2 of 4
Inhalation Anthrax Incubation Period Usually <1 week; may be prolonged for weeks (up to 2 months) Typical Signs/Symptoms (often biphasic, but symptoms may progress rapidly)
Initial phase Non-specific symptoms such as low-grade fever, nonproductive cough, malaise, fatigue, myalgias, profound sweats, chest discomfort (upper respiratory tract symptoms are rare) Maybe rhonchi on exam, otherwise normal Chest X-ray:
o mediastinal widening o pleural effusion (often) o infiltrates (rare)
Subsequent phase 1–5 days after onset of initial symptoms May be preceded by 1–3 days of improvement Abrupt onset of high fever and severe respiratory distress (dyspnea, stridor, cyanosis)Shock, death within 24–36 hours
Laboratory Coordinate all aspects of testing, packaging, and transporting with public health laboratory/Laboratory Response Network (LRN). Obtain specimens appropriate to system affected:
o blood (essential) o pleural fluid o cerebral spinal fluid (CSF) o skin lesion
Clues to diagnosis Gram-positive bacilli on unspun peripheral blood smear or CSF Aerobic blood culture growth of large, gram-positive bacilli provides preliminary identification of Bacillus species.
Treatment (See “Inhalational Anthrax Treatment Protocol”* for specific therapy)
Obtain specimens for culture BEFORE initiating antimicrobial therapy. Initiate antimicrobial therapy immediately upon suspicion. Do NOT use extended-spectrum cephalosporins or trimethoprim/sulfamethoxazole because anthrax may be resistant to these drugs. Supportive care including controlling pleural effusions
Precautions Standard contact precautions
* http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm
Fact Sheet: Anthrax Information for Health Care Providers (continued from previous page)
March 8, 2002 Page 3 of 4
Gastrointestinal Anthrax Incubation Period Usually 1–7 daysTypical Signs/Symptoms
Initial phaseNausea, anorexia, vomiting, and fever progressing to severe abdominal pain, hematemesis, and diarrhea that is almost always bloodyAcute abdomen picture with rebound tenderness may develop. Mesenteric adenopathy on computed tomography (CT) scan likely. Mediastinal widening on chest X-ray has been reported.
Subsequent phase 2–4 days after onset of symptoms, ascites develops as abdominal pain decreases. Shock, death within 2–5 days of onset
Laboratory Coordinate all aspects of testing, packaging, and transporting with public health laboratory/LRN. Obtain specimens appropriate to system affected:
o blood (essential) o ascitic fluid
Clues to diagnosis Gram-positive bacilli on unspun peripheral blood smear or ascitic fluid Pharyngeal swab for pharyngeal form Aerobic blood culture growth of large, gram-positive bacilli provides preliminary identification of Bacillusspecies.
Treatment (See “Inhalational Anthrax Treatment Protocol”* for specific therapy)
Obtain specimens for culture BEFORE initiating antimicrobial therapy. Early (during initial phase) antimicrobial therapy is critical. Do NOT use extended-spectrum cephalosporins or trimethoprim/sulfamethoxazole because anthrax may be resistant to these drugs.
Precautions Standard precautions
* http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm
Fact Sheet: Anthrax Information for Health Care Providers (continued from previous page)
March 8, 2002 Page 4 of 4
Oropharyngeal Anthrax Incubation Period Usually 1–7 days Typical Signs/Symptoms
Initial phase Fever and marked unilateral or bilateral neck swelling caused by regional lymphadenopathy Severe throat pain and dysphagiaUlcers at the base of the tongue, initially edematous and hyperemic
Subsequent phase Ulcers may progress to necrosis Swelling can be severe enough to compromise the airway
Laboratory Coordinate all aspects of testing, packaging, and transporting with public health laboratory/LRN.Obtain specimens appropriate to system affected:
o blood (essential) o throat
Clues to diagnosis Aerobic blood culture growth of large, gram-positive bacilli provides preliminary identification of Bacillus species.
Treatment (See “Inhalational Anthrax Treatment Protocol”* for specific therapy)
Obtain specimens for culture BEFORE initiating antimicrobial therapy. Do NOT use extended-spectrum cephalosporins or trimethoprim/sulfamethoxazole because anthrax may be resistant to these drugs. Supportive care including controlling ascites
Precautions Standard contact precautions
* http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm
For more information, visit www.bt.cdc.gov/agent/anthrax,or call CDC at 800-CDC-INFO (English and Spanish) or 888-232-6348 (TTY).